drugset / Trial / NCT06548997

A Phase I Study of GZR18 Injection in Healthy Subjects

NCT06548997

Phase 1 Completed 57 enrolled Gan and Lee Pharmaceuticals, USA
RandomizedSequentialDouble-blindTreatment

Summary

This trial is conducted in China. The aim of the trial is to evaluate the safety and tolerability of GZR18 injection in healthy subjects following single dose and once-weekly dose for 2 consecutive weeks until reaching the target dose.

Timeline

Start
2021-12-02
Primary completion
2022-10-20
Completion
2022-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Bofanglutide Protein / enzyme biologic 5 ug/kg